# EGFRvIII

Source: https://onco.cc/terms/egfrviii/  
OnCo record `egfrviii` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

EGFRvIII is a mutant, tumour-only version of the EGFR receptor found in about a third of glioblastomas. It is an ideal-looking target, yet every drug against it has failed so far.

## Summary

In-frame deletion of exons 2-7 creating a constitutively active receptor with a tumour-specific junctional epitope. Targeted by rindopepimut (ACT IV negative), EGFRvIII CAR-T (antigen loss), bispecifics (AMG 596), and ADCs (depatuxizumab mafodotin, INTELLANCE-1 negative). Expression is heterogeneous and frequently lost at recurrence.

## Fields

- Kind: Term
- Last checked: 2026-09-06

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/EGFRvIII
- Wikipedia: https://en.wikipedia.org/wiki/EGFRvIII

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- drugs: [Rindopepimut](https://onco.cc/drugs/rindopepimut/)
- terms: [Drug resistance (primary and acquired)](https://onco.cc/terms/resistance/)
- trials: [ACT IV](https://onco.cc/trials/act-iv/)
- technologies: [CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target)](https://onco.cc/technologies/glioma-car-t/)
- bottlenecks: [The brain: barrier and sanctuary](https://onco.cc/bottlenecks/b-brain-delivery/)
- pathways: [Receptor tyrosine kinase activation](https://onco.cc/pathways/rtk-activation/)

---
JSON: https://onco.cc/api/v1/entities/egfrviii.json